Posted date:
We are pleased to announce that Dr. Victor Stone from Takeda Ventures was elected and appointed as a new director at our Ordinary General Meeting of Shareholders on June 16, 2021.
Posted date:
Website updated.
Posted date:
ARTham Therapeutics again receives the rare disease drug development grant from AMED for its ART-001 program (development for the treatment of slow-flow vascular malformations)
ARTham’s clinical program ART-001, an oral selective PI3Kα inhibitor, for slow-flow vascular malformations in both pediatric and adult population was awarded additional three-year R&D grant from “the Japan Agency for Medical Research and Development (AMED) Program for Orphan Drugs prior to Designation”.
Link: https://www.amed.go.jp/koubo/11/02/1102C_00004.html
Slow-flow vascular malformations are benign (non-cancerous) lesions that are present at birth, and may become visible for weeks or months after birth. Unlike hemangiomas, vascular malformations continue to grow slowly throughout life. It has been reported that most patients with slow-flow vascular malformation have a gain-of-function mutation in PI3K pathway, which plays an important pathological role in vascular formation. ART-001 inhibits PI3Kα with high selectivity, being expected to exert clinically meaningful therapeutic effect.
ART-001 program had been supported by AMED for last 3 years and had made a significant progress including new formulation development, completion of Ph-1 clinical trial as well as multiple clinical research to better understand the disease background such as gene mutation and natural history. Ph-2 clinical trial is anticipated to start in third quarter of 2021. ARTham is striving to deliver medicines that matter for patients.
Posted date:
ARTham Therapeutics Presents Phase I Results for both ART-001 and ART-648 at ASCPT 2021 Annual Meeting
YOKOHAMA, January 15, 2021 – ARTham Therapeutics, Inc. will present Phase I results for both ART-648, an investigational PDE4 inhibitor, and ART-001, an investigational PI3Kα inhibitor in a poster session at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Annual Meeting (March 8-17, 2021). ART-648 is an orally-available, selective and potent inhibitor of PDE4 in development for the treatment of bullous pemphigoid and COVID-19. ART-001 is an orally-available selective PI3Kα inhibitor in development for the treatment of slow-flow vascular malformations. Details of the poster presentations are as follows:
Abstract title: PII-040 – The novel PDE4 inhibitor ART-648 exhibits robust target engagement at clinically safe and tolerated doses identified in healthy subjects
Abstract title: PII-041 – Safety and pharmacokinetics of novel PI3Kα inhibitor ART-001 in oral pediatric formulation for the treatment of vascular malformations
Session title: Interactive Poster Hour II
Date & Time: Friday, March 12, 6:00 – 7:00 pm (EST)
About ART-648
ART-648 is an orally-available PDE4 inhibitor that is currently under development for bullous pemphigoid and COVID-19. ART-648 potently and selectively inhibits PDE4 enzyme and exhibits direct “anti-inflammatory,” “antimetabolite,” and “antifibrotic” effects in multiple disease relevant in vitro or in vivo models. In addition, ART-648 possesses superior physico-chemical properties, which contribute to tolerability profile similar or better to marketed PDE4 inhibitors. Phase IIa trials are scheduled to initiate in late 2021.
About ART-001
ART-001 is an orally-available PI3Kα inhibitor that is currently under development for low-flow vascular malformations. ART-001 potently and selectively inhibited PI3Kα and exhibits “antitumor effect” and “anti-angiogenesis effect” in in vitro and in vivo preclinical models. In addition, the excellent pharmacokinetic and safety profile with the new formulation was demonstrated in the Phase I study in healthy adults. The new formulation will also enable administration in pediatric patients. Phase IIa trials are scheduled to initiate in late 2021.
About ARTham Therapeutics
ARTham Therapeutics is a clinical stage biopharmaceutical company that will deliver “medicines that matter” for patients, with a compelling portfolio developed through unraveling hidden value of existing pharma assets. ARTham is a virtual R&D company that seeks the best academic and business partners to rapidly develop high value clinical candidates. The company is headquartered in Yokohama, Japan. For more information, please visit https://www.arthamther.com/en/
Contact
Tel: +81-45-225-8858
info@arthamther.com
Posted date:
Series B round financing to unveil proof-of-concepts of both ART-648 and ART-001 programs
YOKOHAMA, January 15, 2021 – ARTham Therapeutics Inc. (“ARTham”), a clinical stage biopharmaceutical company, has raised 590 million JPY (approx. $5.7 million) in Series B financing lead by Miyako Capital and joined by additional investors including Takeda Pharmaceutical Company, SMBC Venture Capital, Mizuho Capital, Oita Venture Capital and Yokohama Capital.
Phase I clinical trials for both ART-648 and ART-001 have been successfully completed and Phase II trials for these programs are planned to initiate during the second half of 2021. The funds accelerate ARTham’s R&D towards achieving clinical POC of ART-648 and ART-001 for bullous pemphigoid and slow-flow vascular malformations, respectively.
About ARTham Therapeutics
ARTham Therapeutics is a clinical stage biopharmaceutical company that will deliver “medicines that matter” for patients, with a compelling portfolio developed through unraveling hidden value of existing pharma assets. ARTham is a virtual R&D company that seeks the best academic and business partners to rapidly develop high value clinical candidates. The company is headquartered in Yokohama, Japan. For more information, please visit https://www.arthamther.com/en/
Contact
Tel: +81-45-225-8858
info@arthamther.com
